These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 18708992

  • 1. Impact of changing from cyclosporine to tacrolimus on pharmacokinetics of mycophenolic acid in renal transplant recipients with diabetes.
    Park JM, Lake KD, Cibrik DM.
    Ther Drug Monit; 2008 Oct; 30(5):591-6. PubMed ID: 18708992
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid.
    van Gelder T, Klupp J, Barten MJ, Christians U, Morris RE.
    Ther Drug Monit; 2001 Apr; 23(2):119-28. PubMed ID: 11294511
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics of mycophenolic acid and its glucuronide metabolites in stable adult liver transplant recipients with renal dysfunction on a low-dose calcineurin inhibitor regimen and mycophenolate mofetil.
    Beckebaum S, Armstrong VW, Cicinnati VR, Streit F, Klein CG, Gerken G, Paul A, Oellerich M.
    Ther Drug Monit; 2009 Apr; 31(2):205-10. PubMed ID: 19307937
    [Abstract] [Full Text] [Related]

  • 4. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings.
    Zucker K, Rosen A, Tsaroucha A, de Faria L, Roth D, Ciancio G, Esquenazi V, Burke G, Tzakis A, Miller J.
    Transpl Immunol; 1997 Sep; 5(3):225-32. PubMed ID: 9402690
    [Abstract] [Full Text] [Related]

  • 5. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients.
    Kuypers DR, Claes K, Evenepoel P, Maes B, Coosemans W, Pirenne J, Vanrenterghem Y.
    J Clin Pharmacol; 2003 Aug; 43(8):866-80. PubMed ID: 12953344
    [Abstract] [Full Text] [Related]

  • 6. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO, Ehlermann P, Koch A, Remppis A, Katus HA, Dengler TJ.
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine.
    El Haggan W, Ficheux M, Debruyne D, Rognant N, Lobbedez T, Allard C, Coquerel A, Ryckelynck JP, Hurault de Ligny B.
    Transplant Proc; 2005 Mar; 37(2):864-6. PubMed ID: 15848558
    [Abstract] [Full Text] [Related]

  • 8. Effect of cyclosporine on steady-state pharmacokinetics of MPA in renal transplant recipients is not affected by the MPA formulation: analysis based on therapeutic drug monitoring data.
    Trkulja V, Lalić Z, Nađ-Škegro S, Lebo A, Granić P, Lovrić M, Pasini J, Božina N.
    Ther Drug Monit; 2014 Aug; 36(4):456-64. PubMed ID: 24518562
    [Abstract] [Full Text] [Related]

  • 9. Renal graft function and low-dose cyclosporine affect mycophenolic acid pharmacokinetics in kidney transplantation.
    Cortinovis M, Gotti E, Pradini S, Gaspari F, Perico N.
    Transplantation; 2011 Sep 15; 92(5):550-6. PubMed ID: 21709602
    [Abstract] [Full Text] [Related]

  • 10. Best single time points to predict the area-under-the-curve in long-term heart transplant patients taking mycophenolate mofetil in combination with cyclosporine or tacrolimus.
    Mardigyan V, Giannetti N, Cecere R, Besner JG, Cantarovich M.
    J Heart Lung Transplant; 2005 Oct 15; 24(10):1614-8. PubMed ID: 16210138
    [Abstract] [Full Text] [Related]

  • 11. Influence of Calcineurin Inhibitor and Sex on Mycophenolic Acid Pharmacokinetics and Adverse Effects Post-Renal Transplant.
    Meaney CJ, Sudchada P, Consiglio JD, Wilding GE, Cooper LM, Venuto RC, Tornatore KM.
    J Clin Pharmacol; 2019 Oct 15; 59(10):1351-1365. PubMed ID: 31062373
    [Abstract] [Full Text] [Related]

  • 12. Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients.
    Aw MM, Brown NW, Itsuka T, Gonde CE, Adams JE, Heaton ND, Tredger JM, Mieli-Vergani G, Dhawan A.
    Liver Transpl; 2003 Apr 15; 9(4):383-8. PubMed ID: 12682891
    [Abstract] [Full Text] [Related]

  • 13. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T, Durlik M, Szlaska I, Urbanowicz A, Majchrnak J, Gralak B.
    J Clin Pharm Ther; 2006 Feb 15; 31(1):27-34. PubMed ID: 16476117
    [Abstract] [Full Text] [Related]

  • 14. Pharmacodynamic monitoring of the conversion of cyclosporine to tacrolimus in heart and lung transplant recipients.
    Barten MJ, Rahmel A, Garbade J, Bold A, Bittner HB, Dhein S, Mohr FW, Gummert JF.
    Transplant Proc; 2005 Dec 15; 37(10):4532-4. PubMed ID: 16387162
    [Abstract] [Full Text] [Related]

  • 15. Steady-state pharmacokinetics of mycophenolic acid in renal transplant patients: exploratory analysis of the effects of cyclosporine, recipients' and donors' ABCC2 gene variants, and their interactions.
    Božina N, Lalić Z, Nađ-Škegro S, Borić-Bilušić A, Božina T, Kaštelan Ž, Trkulja V.
    Eur J Clin Pharmacol; 2017 Sep 15; 73(9):1129-1140. PubMed ID: 28624888
    [Abstract] [Full Text] [Related]

  • 16. Mycophenolic acid interaction with cyclosporine and tacrolimus in vitro and in vivo: evaluation of additive effects on rat blood lymphocyte function.
    Barten MJ, Shipkova M, Bartsch P, Dhein S, Streit F, Tarnok A, Armstrong VW, Mohr FW, Oellerich M, Gummert JF.
    Ther Drug Monit; 2005 Apr 15; 27(2):123-31. PubMed ID: 15795640
    [Abstract] [Full Text] [Related]

  • 17. Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling.
    Cremers S, Schoemaker R, Scholten E, den Hartigh J, König-Quartel J, van Kan E, Paul L, de Fijter J.
    Br J Clin Pharmacol; 2005 Sep 15; 60(3):249-56. PubMed ID: 16120063
    [Abstract] [Full Text] [Related]

  • 18. The influence of calcineurin inhibitors on mycophenolic acid pharmacokinetics.
    Kuriata-Kordek M, Boratynska M, Falkiewicz K, Porazko T, Urbaniak J, Wozniak M, Patrzalek D, Szyber P, Klinger M.
    Transplant Proc; 2003 Sep 15; 35(6):2369-71. PubMed ID: 14529944
    [Abstract] [Full Text] [Related]

  • 19. Concentrations of mycophenolic acid and glucuronide metabolites under concomitant therapy with cyclosporine or tacrolimus.
    Patel CG, Harmon M, Gohh RY, Akhlaghi F.
    Ther Drug Monit; 2007 Feb 15; 29(1):87-95. PubMed ID: 17304155
    [Abstract] [Full Text] [Related]

  • 20. Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of cyclosporin in renal transplant recipients.
    Kuypers DR, Ekberg H, Grinyó J, Nashan B, Vincenti F, Snell P, Mamelok RD, Bouw RM.
    Clin Pharmacokinet; 2009 Feb 15; 48(5):329-41. PubMed ID: 19566116
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.